The global lacrimal devices market is witnessing steady growth due to the rising prevalence of eye disorders, increasing geriatric population, and growing adoption of minimally invasive ophthalmic procedures. The global lacrimal devices market size was valued at USD 160.77 million in 2025 and is projected to grow from USD 166.39 million in 2026 to USD 219.11 million by 2034, registering a CAGR of 3.5% during the forecast period (2026–2034).

Lacrimal devices are specialized ophthalmic instruments used to diagnose and treat disorders affecting the tear drainage system, including dry eye syndrome, glaucoma, epiphora, and lacrimal duct obstruction. These devices include stents, intubation sets, cannulas, dilators, and other surgical instruments that help restore normal tear drainage and improve patient comfort. Technological advancements in ophthalmic procedures and increasing awareness regarding eye health are expected to support market growth throughout the forecast period.

Market Drivers

One of the primary factors driving the lacrimal devices market is the increasing prevalence of ophthalmic disorders worldwide. The growing number of patients suffering from dry eye syndrome, glaucoma, lacrimal gland inflammation, and tear duct obstruction is creating substantial demand for advanced lacrimal treatment devices. The aging global population is particularly susceptible to these conditions, further boosting market growth.

Another significant growth driver is the rising geriatric population. As people age, tear production naturally declines, increasing the risk of dry eye disease and other lacrimal disorders. The growing elderly population, combined with increasing life expectancy, is expected to generate sustained demand for minimally invasive lacrimal procedures and specialized ophthalmic devices.

The increasing adoption of minimally invasive ophthalmic surgeries is also contributing to market expansion. Healthcare providers are increasingly utilizing advanced lacrimal stents, intubation systems, and precision surgical instruments that improve treatment outcomes while reducing recovery time. These innovations have significantly enhanced the effectiveness and safety of lacrimal procedures.

Furthermore, continuous investments in ophthalmic research, improvements in healthcare infrastructure, and growing awareness regarding early diagnosis and treatment of eye diseases are creating new growth opportunities for manufacturers operating in the global lacrimal devices market.

Market Challenges

Despite favorable growth prospects, the lacrimal devices market faces several challenges.

One of the major restraints is the potential risk of complications associated with lacrimal procedures. Patients may experience irritation, discomfort, scarring, infection, or other post-surgical complications, which may affect treatment adoption in certain cases.

Another challenge is the high cost associated with advanced ophthalmic procedures and specialized lacrimal devices, particularly in developing countries where access to specialized eye care remains limited.

Additionally, stringent regulatory requirements for ophthalmic medical devices and lengthy product approval processes may delay the commercialization of innovative products.

Market Segmentation

By Product

• Intubation Sets
• Stents and Tubes
• Cannula and Spatula
• Dilators

The stents and tubes segment accounts for the largest market share owing to the increasing number of lacrimal drainage procedures and the widespread use of these devices in treating tear duct obstruction and related ophthalmic conditions.

By Application

• Glaucoma
• Dry Eye
• Lacrimal Gland Inflammation
• Epiphora
• Others

The glaucoma segment dominates the market due to the increasing global prevalence of glaucoma and the growing use of minimally invasive surgical procedures requiring advanced lacrimal devices.

By End User

• Hospitals
• Diagnostic Centers
• Ambulatory Care Centers (ACC)

The hospitals segment holds the largest market share owing to the availability of specialized ophthalmologists, advanced surgical facilities, and increasing patient volume for eye care procedures. Favorable reimbursement policies in several developed countries further support segment growth.

Regional Insights

North America

North America dominates the global lacrimal devices market due to its well-established healthcare infrastructure, high adoption of advanced ophthalmic technologies, increasing prevalence of eye diseases, and strong presence of leading medical device manufacturers. Growing healthcare expenditure and continuous technological innovation continue to support regional market growth.

Europe

Europe represents a significant market driven by rising demand for advanced ophthalmic treatments, increasing research and development activities, growing elderly populations, and expanding access to specialized eye care services.

Asia-Pacific

Asia-Pacific is expected to witness the fastest growth during the forecast period owing to improving healthcare infrastructure, rising healthcare expenditure, increasing awareness regarding eye health, and the growing prevalence of age-related eye disorders across China, India, Japan, and other emerging economies.

Latin America, Middle East, and Africa

These regions are emerging markets supported by expanding healthcare infrastructure, improving access to ophthalmic care, increasing government healthcare initiatives, and growing awareness regarding the diagnosis and treatment of lacrimal disorders.

Key Players Analysis

The lacrimal devices market is moderately competitive, with leading companies focusing on product innovation, minimally invasive surgical technologies, strategic partnerships, and expanding their global distribution networks. Continuous investments in research and development are enabling manufacturers to introduce advanced ophthalmic devices that improve surgical precision and patient outcomes.

Major companies operating in the market include:

• FCI Ophthalmic
• Kaneka Corporation
• Lacrimedics, Inc.
• Cook Group
• BVI
• Rumex International
• Bess Medical Technology GmbH
• Alcon
• Bausch + Lomb Incorporated
• B. Braun Melsungen AG

These companies continue investing in advanced lacrimal device technologies, strengthening their product portfolios, and expanding their global presence to address the growing demand for effective ophthalmic treatment solutions.

For Detailed Insights, Visit:

https://straitsresearch.com/report/lacrimal-devices-market

About Us

Straits Research is a leading market research and intelligence organization specializing in research, analytics, and advisory services. The company provides comprehensive market reports, industry insights, and strategic business intelligence across multiple industries, helping organizations identify growth opportunities and make informed business decisions.

Contact Us

Email: sales@straitsresearch.com

Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)